Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation
- Conditions
- Smoking Cessation
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 533
- Registration Number
- NCT00464256
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: volinanserinDrug: placebo
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 604
- Registration Number
- NCT00464243
- Locations
- 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: VolinanserinDrug: Placebo
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1847
- Registration Number
- NCT00464061
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇭🇰Anofi-Aventis Administrative Office, Causeway Bay, Hong Kong
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
- Conditions
- Ductal Carcinoma
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00461344
SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.
- Conditions
- Colles' Fracture
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 141
- Registration Number
- NCT00460733
- Locations
- 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
- Conditions
- Maintenance of Smoking Cessation
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4850
- Registration Number
- NCT00459173
- Locations
- 🇨🇦
Sanofi-Aventis, Laval, Quebec, Canada
Japanese Dose-Response Study of Rimonabant in Obese Patients
- Conditions
- Obesity
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 527
- Registration Number
- NCT00459004
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch
- Conditions
- Smoking Cessation
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 755
- Registration Number
- NCT00458718
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
- Conditions
- ObesityMicroalbuminuriaDiabetes Mellitus, Type 2Dyslipidemia
- Interventions
- Drug: RimonabantDrug: Placebo
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 174
- Registration Number
- NCT00458081
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children
- Conditions
- Gastroenteritis
- Interventions
- Other: Oral rehydration therapyDrug: Bacillus Clausii
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 264
- Registration Number
- NCT00457353
- Locations
- 🇮🇳
Sanofi-Aventis, Mumbai, India